Latest insights

Over the past twenty-five years, the medical biotechnology sector has profoundly transformed the therapeutic landscape. From the fight against cancer to the development of Covid-19 vaccines in record time, advances in biopharma have changed the outcome for millions of patients worldwide.

“Volatility” would be the key word to describe global markets in April, as the set of tariffs announced by President Trump were broader and more punitive than expected.

PFAS have been widely used for decades due to their unique properties in various domestic and industrial applications. They are resistant to water and virtually indestructible. They are also seen as the poison of the century. Where do we stand in terms of regulation? What are the PFAS-related risks? Where are the opportunities?

Since the last committee on March 11th, European markets have fallen sharply, due to Donald Trump’s announcements regarding US tariffs on April 2nd.

According to the Institute for Economics & Peace, there are 56 active conflicts in the world, the greatest number since the end of World War II. Increasingly complex geopolitics and ReArm Europe are keeping investors on our toes, analytically.

“Uncertainty” was probably the most important driver behind the stock market’s behaviour over the past four weeks.

In January, European equities closed the month higher, outperforming the US and narrowing part of the valuation gap between the two sides of the Atlantic. In addition to attractive valuation multiples, the eurozone has benefited from improving macro data (the composite PMI edged into expansionary territory at 50.2 in January and retail sales have risen for five consecutive months) and the ongoing rate-cutting cycle from the European Central Bank (ECB), while the Fed has decided to pause rate cuts.

Since the US presidential elections, US equities have been on an uptrend driven by a certain optimism, as the expectation of tax cuts and deregulation have fuelled the hope of accelerated corporate earnings growth.